Pioneering Kidney Treatment: How CRRT is Shaping Renal Care in Critical Conditions

Comments · 31 Views

According to a WHO, acute kidney injury, a potentially life-threatening condition in which the kidneys cease working and uremic and fluid toxins build up in the body, is one of the many COVID-19 side effects. As a result, as the COVID-19 outbreak expands, demand for CRRT will continue to c

Continuous Renal Replacement Therapy Industry Overview

 

The global continuous renal replacement therapy market size is anticipated to reach USD 2,603.8 million by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.6% from 2023 to 2030. The primary driving factors for market growth are increasing prevalence of congestive heart failure and acute renal failure. The COVID-19 is expected to have a positive impact on market due to increasing prevalence of acute kidney injury. According to a WHO, acute kidney injury, a potentially life-threatening condition in which the kidneys cease working and uremic and fluid toxins build up in the body, is one of the many COVID-19 side effects. As a result, as the COVID-19 outbreak expands, demand for CRRT will continue to climb.

 

Gather more insights about the market drivers, restrains and growth of the Continuous Renal Replacement Therapy Market

 

Over the forecast period, technological advancements are expected to be a crucial driver in the growth of the market. For example, in August 2020, Baxter International Inc., a global leader in acute care, announced that Regiocit, the company's replacement solution containing citrate for extracorporeal circuit regional citrate anticoagulation, has acquired an Emergency Use Authorization (EUA) from the U.S Food and Drug Administration (FDA). Regiocit is exclusively approved for use as a replacement solution in adult patients receiving Continuous Renal Replacement Therapy (CRRT) and who require regional citrate anticoagulation during the COVID-19 pandemic, according to the EUA.

 

Browse through Grand View Research's Medical Devices Industry Research Reports.



Continuous Renal Replacement Therapy Market Segmentation

 

Grand View Research has segmented the global continuous renal replacement therapy market on the basis of product, modality, and region:

 

Continuous Renal Replacement Therapy Product Outlook (Revenue, USD Million, 2018 - 2030)

 

  • System
  • Consumables

 

Continuous Renal Replacement Therapy Modality Outlook (Revenue, USD Million, 2018 - 2030)

 

  • Slow Continuous Ultra-Filtration (SCUF)
  • Continuous Venovenous Hemofiltration (CVVH)
  • Continuous Venovenous Hemodialysis (CVVHD)
  • Continuous Venovenous Hemodiafiltration (CVVHDF)

 

Continuous Renal Replacement Therapy Regional Outlook (Revenue, USD Million, 2018 - 2030)

 

  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Sweden
    • Norway
    • Denmark
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Thailand
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • UAE
    • Kuwait

 

 

Key Companies profiled:

 

  • Braun Melsungen AG
  • Baxter International, Inc.
  • Fresenius Medical Care AG Co. KGaA
  • Asahi Kasei Corporation
  • NIPRO Corporation
  • Toray Medical Co., Ltd
  • NxStage Medical, Inc.
  • Medtronic PLC

 

 

Order a free sample PDF of the Continuous Renal Replacement Therapy Market Intelligence Study, published by Grand View Research.

 

Comments